Trials / Not Yet Recruiting
Not Yet RecruitingNCT07463573
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 466 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLC5508 | QLC5508 Injection |
| DRUG | Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride) | Investigator's Choice of Chemotherapy (ICC) (docetaxel, paclitaxel, or Irinotecan Hydrochloride) |
Timeline
- Start date
- 2026-04-05
- Primary completion
- 2028-06-05
- Completion
- 2029-07-05
- First posted
- 2026-03-11
- Last updated
- 2026-03-11
Source: ClinicalTrials.gov record NCT07463573. Inclusion in this directory is not an endorsement.